Emzor Pharmaceutical Industries Limited, an important player in the pharmaceutical industry in Africa, has expressed his unwavering commitment to eradicate malaria completely from Nigeria and, by extension, sub -Saharan Africa.
The company reiterated this commitment on Friday through its president, the Board of Directors, Mr. Emeka Okoli, in commemoration of World Malaria Day this year, observed worldwide, April 25.
According to him, Emzor is resolved in the support efforts of state and non -state actors inside and outside Nigeria aimed at fighting the high load of malaria in sub -Saharan Africa.
He pointed out that this year's World Malaria Day, “Malaria ends with us: reinvirming, reinventing, rekindling,” is closely aligned with the company's vision of having a tangible impact on the global struggle against the disease.
In revealing that the company has been at the forefront of the prevention and treatment of malaria, producing high quality antipalúdico medications that are accessible and affordable, added: “Our dedication is reflected in our investment in research, development and distribution networks of wide range, which have played a crucial role in the reduction of malaria.”
As part of its activities for World Malaria Day of this year, the company organized a series of community dissemination events, which include a health walk, free medical exams and the distribution of antipalúdic drugs to vulnerable populations.
Malaria remains a main cause of death among pregnant women and children under five in Africa.
Emzor's long data initiatives in malaria control include the production of essential antipalúdico medications aimed at reducing maternal and child mortality rates.
The Company Currently produces Over 20 Antimalarial Drugs, Including Maldox (Sulfadoxine/Pyrimethamine), Lokmal (Artemether/Lummefantrine), Pyramal TS (dihydroartemisinin/piperaquine), Diasunate (Artesunate/Amodiaquine), and Chloroquine, in varied Such as tablets, suspensions, and dispersible tablets.
The company's multimillionaire investment in the manufacture of active pharmaceutical ingredients (API) in its new plant in Sagamu, state of Ogun, further underlines its commitment to combat the disease in Africa.
Also read: Ekiti vaccine to more than 266,429 girls against HPV
“Then, with the initial production of antipalúdic APIs that include arteméter, lumefantrine, sulfadoxin and pyrimethamine, we are convinced that the project will substantially reduce the dependence of the country of imports of Asia, supports the growth of GDP, reduces the demand for currencies and the cost of production and access to medications by people who need them.”
He stressed that the fact that approximately 95% of all cases of malaria and 96% of malaria -related deaths occur in Africa points to the disease predominantly an African problem, hence the need for solutions to originate largely to the continent.
“That is why we are playing our role, and a pioneer in the API project in the continent definitely fits this,” Okoli emphasized.
Also speaking, the marketing and strategy chief, Mr. Kunle Faloye, highlighted other activities that Emzor is undertaking to combat malaria, especially in Nigeria.
According to him, “Emzor works in association with local governments, NGOs and communities to implement base dissemination programs focused on education, prevention, diagnosis and treatment.
“The company continues to provide subsidized and free medications to pregnant women and children, the groups most vulnerable to malaria.”
However, he promised that the company would continue to innovate, collaborate and invest in sustainable medical care solutions that improve lives in Nigeria and Africa as a whole.
Read too Main stories Of the Nigerian Tribune